Antisense Therapy
Synthetic Oligonucleotides Advance Antisense Therapeutics
Published in Gene Therapy Weekly, March 29th, 1999
D.K. Monteith and colleagues from ISIS Pharmaceuticals, California, evaluated progress in the development of synthetic ODNs ("Synthetic Oligonucleotides: The Development of Antisense Therapeutics," Toxicologic Pathology, January-February 1999;27(1):8-13).
"Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) are currently being evaluated in clinical trials for cancer, inflammation, and viral diseases," wrote Monteith et al. "These macromolecules afford a unique opportunity to treat disease at the molecular level."
According...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1999-03-29)
More Articles from Gene Therapy Weekly
- Antisense Therapy
Therapy Combines Gene Targeting/Radiotherapy for Tumor Destruction - Cancer Gene Therapy
Cytokine Gene Therapy Tackles Cancer In Vivo - Combination Therapy
Ionizing Radiation Improves Gene Delivery to Cancer Cells - Vector Development
F(ab'gamma)(2) Antibody Mediates AAV Transduction - Endothelial Cells
Tie Promoter Activity Has Potential for Cell-Specific Gene Expression - Genomics
HCV Protein's Impact on Gene Expression Examined - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
